Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study
N Kogame, PO Guimaraes, R Modolo… - Cardiovascular …, 2020 - jacc.org
Objectives The aim of this study was to evaluate the hypothesis that prasugrel monotherapy
following successful everolimus-eluting stent implantation is feasible and safe in patients …
following successful everolimus-eluting stent implantation is feasible and safe in patients …
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement
KN Garratt, WD Weaver, RG Jenkins, TK Pow, L Mauri… - Circulation, 2015 - Am Heart Assoc
Background—The TAXUS Liberté Post Approval Study (TL-PAS) contributed patients treated
with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy …
with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy …
Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel
G Parodi, B Bellandi, F Venditti, N Carrabba… - The American journal of …, 2012 - Elsevier
Recent guidelines have recommended the use of aspirin and prasugrel in patients with
acute coronary syndromes undergoing percutaneous coronary intervention. However …
acute coronary syndromes undergoing percutaneous coronary intervention. However …
An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial
M Natsuaki, H Watanabe, T Morimoto, K Yamamoto… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after
percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in …
percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in …
6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for …
R Didier, MC Morice, P Barragan, AAL Noryani… - Cardiovascular …, 2017 - jacc.org
Objectives The aim of this study was to test the hypothesis that 6-month dual antiplatelet
therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background …
therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background …
6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial
M Gilard, P Barragan, AAL Noryani, HA Noor… - Journal of the American …, 2015 - jacc.org
Background: The currently recommended duration of dual antiplatelet therapy (DAPT) in
drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis …
drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis …
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study
Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …
[HTML][HTML] Prasugrel versus clopidogrel in patients with acute coronary syndromes
SD Wiviott, E Braunwald, CH McCabe… - … England Journal of …, 2007 - Mass Medical Soc
Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of
treatment to prevent thrombotic complications of acute coronary syndromes and …
treatment to prevent thrombotic complications of acute coronary syndromes and …
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study
G Montalescot, JP Collet, P Ecollan… - Journal of the American …, 2014 - jacc.org
Background: After percutaneous coronary intervention (PCI) for non–ST-segment elevation
myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin is …
myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin is …
[HTML][HTML] Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
L Mauri, DJ Kereiakes, RW Yeh… - … England Journal of …, 2014 - Mass Medical Soc
Background Dual antiplatelet therapy is recommended after coronary stenting to prevent
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are …
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are …